University Of Cologne
Clinical trials sponsored by University Of Cologne, explained in plain language.
-
New drug combo after transplant shows promise for tough hodgkin lymphoma
Disease control CompletedThis study tested whether giving the drug brentuximab vedotin for up to a year after a stem cell transplant could help control Hodgkin lymphoma that had returned or not responded to treatment. 14 adults took part. The goal was to see if this approach could lower the chance of the…
Phase: PHASE2 • Sponsor: University of Cologne • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
ER study reveals hidden dangers of treating low sodium
Knowledge-focused CompletedThis study looked back at the records of 1,000 adults who came to the emergency room with very low sodium levels. The goal was to find out how many had brain swelling from the low sodium itself, and how many later developed nerve damage from correcting the sodium too quickly. Res…
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New registry tracks kidney damage in COVID-19 patients
Knowledge-focused CompletedThis completed registry study collected data from 500 COVID-19 patients to learn how the virus affects kidney function. Researchers aimed to identify risk factors and track outcomes. The findings may help guide future treatment and care for kidney complications in COVID-19.
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Low sodium levels may disrupt heart rhythms, study finds
Knowledge-focused CompletedThis study examined 250 adults with dangerously low sodium levels to see how it changes their heart's electrical signals (ECG). Researchers compared ECGs taken when sodium was low and after it was corrected. The goal was to understand which heart rhythm changes occur and whether …
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Study reveals tricky platelet swings in blood disorder drug response
Knowledge-focused CompletedThis study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessar…
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:26 UTC